Treatment of patients with rare diseases and undergoing continuous replacement therapy (27 03 03 06) State purchase of recombinant antihemophilic factor VIII concentrate (financing will be carried out within the allocations approved by the 2027 state budget). Treatment of patients with rare diseases and undergoing continuous replacement therapy (27 03 03 06) - recombinant antihemophilic factor VIII concentrate (funding will be implemented within the limits of appropriations...
- Agency
- georgia_procurement
- Full Agency
- LEPL National Health Agency
- Country
- Georgia
- Deadline
- 15-Oct-2026 12:30
- Published
- 10-Sep-2026
- Reference
- 701196
- Est. Value
- 4400000
- Source ID
- NAT260019067
Notice Overview
Treatment of patients with rare diseases and undergoing continuous replacement therapy (27 03 03 06) State purchase of recombinant antihemophilic factor VIII concentrate (financing will be carried out within the allocations approved by the 2027 state budget). Treatment of patients with rare diseases
View the full notice
Full description, contacts and procurement documents are available to signed-in members.